The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Brief Psychiatric Rating Scale

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Brief Psychiatric Rating Scale


Psychiatry related information on Brief Psychiatric Rating Scale


High impact information on Brief Psychiatric Rating Scale


Chemical compound and disease context of Brief Psychiatric Rating Scale


Biological context of Brief Psychiatric Rating Scale


Gene context of Brief Psychiatric Rating Scale


Analytical, diagnostic and therapeutic context of Brief Psychiatric Rating Scale


  1. A cost-effectiveness clinical decision analysis model for schizophrenia. Palmer, C.S., Revicki, D.A., Genduso, L.A., Hamilton, S.H., Brown, R.E. The American journal of managed care. (1998) [Pubmed]
  2. Parenteral haloperidol in psychiatric emergencies. Double-blind comparison with chlorpromazine. Gerstenzang, M.L., Krulisky, T.V. Diseases of the nervous system. (1977) [Pubmed]
  3. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Devanand, D.P., Marder, K., Michaels, K.S., Sackeim, H.A., Bell, K., Sullivan, M.A., Cooper, T.B., Pelton, G.H., Mayeux, R. The American journal of psychiatry. (1998) [Pubmed]
  4. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Brown, E.S., J Woolston, D., Frol, A., Bobadilla, L., Khan, D.A., Hanczyc, M., Rush, A.J., Fleckenstein, J., Babcock, E., Cullum, C.M. Biol. Psychiatry (2004) [Pubmed]
  5. Adverse effects of fenfluramine in treatment refractory schizophrenia. Marshall, B.D., Glynn, S.M., Midha, K.K., Hubbard, J.W., Bowen, L.L., Banzett, L., Mintz, J., Liberman, R.P. Journal of clinical psychopharmacology. (1989) [Pubmed]
  6. Acutely psychotic patients receiving high-dose haloperidol therapy. Remington, G., Pollock, B., Voineskos, G., Reed, K., Coulter, K. Journal of clinical psychopharmacology. (1993) [Pubmed]
  7. Social cue perception and intelligence in schizophrenia. Corrigan, P.W. Schizophr. Res. (1994) [Pubmed]
  8. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Hsiao, J.K., Colison, J., Bartko, J.J., Doran, A.R., Konicki, P.E., Potter, W.Z., Pickar, D. Arch. Gen. Psychiatry (1993) [Pubmed]
  9. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Buchsbaum, M.S., Potkin, S.G., Siegel, B.V., Lohr, J., Katz, M., Gottschalk, L.A., Gulasekaram, B., Marshall, J.F., Lottenberg, S., Teng, C.Y. Arch. Gen. Psychiatry (1992) [Pubmed]
  10. Valproate in the treatment of acute mania. A placebo-controlled study. Pope, H.G., McElroy, S.L., Keck, P.E., Hudson, J.I. Arch. Gen. Psychiatry (1991) [Pubmed]
  11. Chlorpromazine levels and the outcome of treatment in schizophrenic patients. May, P.R., Van Putten, T., Jenden, D.J., Yale, C., Dixon, W.J. Arch. Gen. Psychiatry (1981) [Pubmed]
  12. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients. van Kammen, D.P., Docherty, J.P., Marder, S.R., Schulz, S.C., Bunney, W.E. Arch. Gen. Psychiatry (1980) [Pubmed]
  13. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Klein, E., Bental, E., Lerer, B., Belmaker, R.H. Arch. Gen. Psychiatry (1984) [Pubmed]
  14. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Van Putten, T., May, P.R. Arch. Gen. Psychiatry (1978) [Pubmed]
  15. Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Biederman, J., Lerner, Y., Belmaker, R.H. Arch. Gen. Psychiatry (1979) [Pubmed]
  16. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Pickar, D., Breier, A., Hsiao, J.K., Doran, A.R., Wolkowitz, O.M., Pato, C.N., Konicki, P.E., Potter, W.Z. Arch. Gen. Psychiatry (1990) [Pubmed]
  17. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Breier, A.F., Malhotra, A.K., Su, T.P., Pinals, D.A., Elman, I., Adler, C.M., Lafargue, R.T., Clifton, A., Pickar, D. The American journal of psychiatry. (1999) [Pubmed]
  18. Effects of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics. Kausen, J., Zimmermann, P., Fünfgeld, E.W., Klenke, D., Henkel, H. Neuropsychobiology (1984) [Pubmed]
  19. Association study of a functional catechol-O-methyltransferase genetic polymorphism with age of onset, cognitive function, symptomatology and prognosis in chronic schizophrenia. Tsai, S.J., Hong, C.J., Liao, D.L., Lai, I.C., Liou, Y.J. Neuropsychobiology (2004) [Pubmed]
  20. Elevated cerebrospinal fluid SNAP-25 in schizophrenia. Thompson, P.M., Kelley, M., Yao, J., Tsai, G., van Kammen, D.P. Biol. Psychiatry (2003) [Pubmed]
  21. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Erbağci, A.B., Herken, H., Köylüoglu, O., Yilmaz, N., Tarakçioglu, M. Mediators of inflammation. (2001) [Pubmed]
  22. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. Nordström, A.L., Farde, L. Journal of clinical psychopharmacology. (1998) [Pubmed]
  23. Effects of thyrotropin-releasing hormone in chronic schizophrenic patients. Kobayashi, K., Nakaoka, K., Tsuji, H., Shohmori, T. Acta Med. Okayama (1980) [Pubmed]
  24. The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report. Malhotra, A.K., Breier, A., Goldman, D., Picken, L., Pickar, D. Neuropsychopharmacology (1998) [Pubmed]
  25. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. Potkin, S.G., Fleming, K., Jin, Y., Gulasekaram, B. Journal of clinical psychopharmacology. (2001) [Pubmed]
  26. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. Yasui, N., Kondo, T., Otani, K., Furukori, H., Mihara, K., Suzuki, A., Kaneko, S., Inoue, Y. Journal of clinical psychopharmacology. (1999) [Pubmed]
  27. Quantitative EEG and BPRS data following Haldol-Decanoate administration in schizophrenics. Schellenberg, R., Milch, W., Schwarz, A., Schober, F., Dimpfel, W. International clinical psychopharmacology. (1994) [Pubmed]
  28. Association between delta waves during sleep and negative symptoms in schizophrenia. Pharmaco-eeg studies by using structurally different hypnotics. Kato, M., Kajimura, N., Okuma, T., Sekimoto, M., Watanabe, T., Yamadera, H., Takahashi, K. Neuropsychobiology (1999) [Pubmed]
  29. Open label study of the effect of amantadine on weight gain induced by olanzapine. Bahk, W.M., Lee, K.U., Chae, J.H., Pae, C.U., Jun, T., Kim, K.S. Psychiatry and clinical neurosciences. (2004) [Pubmed]
WikiGenes - Universities